SciELO - Scientific Electronic Library Online

 
vol.23 número1Tumor del estroma gastrointestinal (GIST) en yeyunoManejo profiláctico de herida quirúrgica con terapia por presión negativa en cirugía abdominal de emergencia: ¿Realmente es útil? índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista de la Facultad de Medicina Humana

versión impresa ISSN 1814-5469versión On-line ISSN 2308-0531

Rev. Fac. Med. Hum. vol.23 no.1 Lima ene./mar. 2023  Epub 25-Ene-2023

http://dx.doi.org/10.25176/rfmh.v23i1.3620 

Letter to the editor

Nongenetic causes of hypertyrosinemia that must be considered when interpreting a finding of elevated urinary tyrosine

Manuel André Virú-Loza1  2  , Pediatric physician specializing in Endocrinology, Master of Science in Epidemiological Research

1Departamento de Pediatría, Hospital Nacional Edgardo Rebagliati Martins. Lima, Perú.

2Facultad de Medicina Humana, Universidad Ricardo Palma. Lima, Perú.

Mr Editor:

In several countries newborns are screened for tyrosinemia type 1 using tyrosine as a primary marker1. In some situations elevated tyrosine levels in blood are discovered due to elevated tyrosine in a metabolic urine screening2. In Peru, some pediatric patients suspected of having a genetic condition (inborn error of metabolism) undergo a metabolic urine screening that includes - among other things - qualitative detection of tyrosine. However, when there are elevated levels of tyrosine in urine this does not always mean that the patient has a genetic condition2,3. Most often hypertyrosinemia has a non-genetic origin2. Therefore, it is important to review the non-genetic causes of hypertyrosinemia and thus avoid potential misinterpretations of this finding.

The genetic entities associated with increased levels of tyrosine are those that generate an enzymatic deficiency in the degradation of tyrosine, within which tyrosinemias type I, II or III are included2,3. However, elevated tyrosine levels in the blood usually have a nongenetic cause2. The most common non-genetic cause of increased tyrosine levels in the blood is transient tyrosinemia of the newborn2. This is due to immaturity of enzymes involved in tyrosine degradation2,3- such as 4-hydroxyphenylpyruvate dioxygenase4- such as 4-hydroxyphenylpyruvate dioxygenase4.

It should be noted that two full-term infants have been reported to have received high-protein diets (3 to 4 times more than recommended), so the tyrosine concentration was > 10 times normal5. Plasma tyrosine quickly returned to normal after switching to an appropriate formula5. Therefore, even in full-term infants, a diet high in protein is a risk factor for transient tyrosinemia in the newborn5. In fact, some authors point out that in general, hypertyrosinemia could be caused by a diet with sufficiently high levels of proteins3and by vitamin C deficiency2,4.

Transient tyrosinemia of the newborn resolves spontaneously and no significant negative effects are generally observed, even more so if hypertyrosinemia has been maintained only for a short period4,5. However, mild developmental delay4and learning disabilities have been reported after 9 years of follow-up, especially in those with very high tyrosine levels (>1100 umol/L)5, as increased levels of tyrosine in the blood apparently do not cause disease if they are < 500 uM2. Although the resolution is spontaneous, it should be noted that there is a rapid response to pharmacological doses of vitamin C2.

Liver dysfunction or failure of any cause can lead to elevated tyrosine in the blood and increased excretion of tyrosine metabolites in urine2-4. LTyrosine levels in these cases are usually < 500 uM2. Because the latter is also observed in hereditary tyrosinemia type 1 (fumaryl acetoacetate hydrolase deficiency), in cases of liver damage the measurement of plasma alpha-fetoprotein and urine succinyacetone is important to define the cause2.

Hypertyrosinemia may also occur in other situations, such as a blood sample without previous fasting (postprandial sample)2,4, hyperthyroidism2,4and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexanedione) therapy2. Therefore, there are non-genetic causes of hypertyrosinemia that must be considered to avoid false positives.

REFERENCES

1. La Marca G, Malvagia S, Pasquini E, Cavicchi C, Morrone A, Ciani F, et al. Newborn Screening for Tyrosinemia Type I: Further Evidence that Succinylacetone Determination on Blood Spot Is Essential. JIMD Rep. 2011;1:107-9. https://doi.org/10.1007/8904_2011_24 [ Links ]

2. Grompe M. The pathophysiology and treatment of hereditary tyrosinemia type 1. Semin Liver Dis. 2001;21(4):563-71. https://doi.org/10.1055/s-2001-19035 [ Links ]

3. Sniderman King L, Trahms C, Scott C. Tyrosinemia Type I [Internet]. 2006 Jul 24 [Updated 2017 May 25]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews(r) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1515/ [ Links ]

4. Russo PA, Mitchell GA, Tanguay RM. Tyrosinemia: A review. Pediatr Dev Pathol. 2001;4(3):212-21. https://doi.org/10.1007/s100240010146 [ Links ]

5. Techakittiroj C, Cunningham A, Hooper PF, Andersson HC, Thoene J. High protein diet mimics hypertyrosinemia in newborn infants. J Pediatr. 2005;146(2):281-2. https://doi.org/10.1016/j.jpeds.2004.10.013 [ Links ]

Financing: Self-financced.

8 Article published by the Journal of the faculty of Human Medicine of the Ricardo Palma University. It is an open access article, distributed under the terms of the Creatvie Commons license: Creative Commons Attribution 4.0 International, CC BY 4.0(https://creativecommons.org/licenses/by/1.0/), that allows non-commercial use, distribution and reproduction in any medium, provided that the original work is duly cited. For commercial use, please contact revista.medicina@urp.edu.pe.

Received: February 28, 2021; Accepted: December 10, 2022

Corresponding author: Manuel André Virú-Loza. Address: Jr. Piedra Bigua 2241-A, San Juan de Lurigancho. Phone number: (01) 2654901. E-mail:m.andre.viru@gmail.com

Authorship contributions: The author made the conception, search for information, drafting and approval of the final version of the article.

Conflicts of interest: Author declares no conflicts of interest.

Creative Commons License Este es un artículo publicado en acceso abierto bajo una licencia Creative Commons